trending Market Intelligence /marketintelligence/en/news-insights/trending/yhofnxjfb40zw0iarumy2g2 content esgSubNav
In This List

ProMIS Neurosciences raises C$1.5M in common stock warrant exercise

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ProMIS Neurosciences raises C$1.5M in common stock warrant exercise

ProMIS Neurosciences Inc. raised nearly C$1.5 million in proceeds related to an exercise of common stock warrants.

The warrants were exercised at 17 cents, 20 cents or 30 cents.

ProMIS is a Canadian biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis. The company is focused on developing PMN310 for treating Alzheimer's disease.